Norman Eansor

Novus Biologicals LLC develops and markets antibodies for scientific researchers in government, university, and biotech labs worldwide. It provides primary antibodies, secondary antibodies, antibody packs, lysates, peptides and proteins, antibody pairs, kits, RNAi, slides, isotype controls, support products, and various research reagents. Novus products are used in various research areas, including apoptosis, autophagy, cancer, DNA repair, epigenetics, epitope tags, GPCR, hypoxia, lipid and metabolism, loading controls, neuroscience, stem cell markers, cellular markers, immunology, and protein turnover. The company was founded by Karen M. Padgett in 1996 and is headquartered Littleton, CO.

Part of Cardinal Health, Inc., this company manufactures and distributes hospital equipment. The company is based in Memphis, TN.

Cambrex Corp. engages in the provision of products, services, and technologies to accelerate and improve the development and commercialization of new and generic therapeutics. It supplies to innovator and generic pharmaceutical companies. Its products include generic and branded APIs, controlled substances, chiral compounds, high potency APIs, and advanced intermediates. The company was founded by Arthur Mendolia and Cyril C. Baldwin Jr. in 1981 and is headquartered in East Rutherford, NJ.

R.P. Scherer Corp. Develops and manufactures oral drug delivery systems. The company offers different types of medical services and products. It has approximately 4 medical faculties in United States. The company is located in Troy, MI

B-MoGen Biotechnologies, Inc. provides gene editing solutions for antibody validation, human disease research, gene transfer, and mitochondrial DNA editing. It offers custom vector generation services that include multi-gene expression vectors that are delivered via the proven sleeping beauty transposon system; and custom gene targeting vectors. The company was founded by David A. Largaespada and Branden S. Moriarity in 2015 and is headquartered in Minneapolis, MN.

CyVek, Inc. engages in the development of a novel, platform technology for measuring analytes in biological samples. It is a biotechnology company dedicated to the advancement of healthcare by empowering researchers and clinicians with a disruptive technology for performing multi-analyte immunoassays. The firm is a versatile platform that can be quickly and easily configured for diverse applications such as rapid diagnostic tests, multi-sample multi-analyte tests, or routine ELISA-like tests, for use in both research and clinical settings. The company offers an breadth of applications, from life science research to drug discovery, personalized medicine, diagnostics, and point-of-care testing. CyVek was founded by Per J. Hellsund, Rajiv Pandey and Marty Andrew Putnam in 2010 and is headquartered in Wallingford, CT.